Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Castration-resistant prostate cancer (CRPC) requires novel treatments beyond docetaxel and enzalutamide.
• Histone deacetylase (HDAC) inhibitors show promise in hematological cancers but have failed in solid tumors like prostate cancer.
• Despite HDAC overexpression in CRPC, clinical trials of four HDAC inhibitors (vorinostat, pracinostat, panobinostat, romidepsin) were not recommended due to toxicity and disease progression.

Purpose of the Study:

• To assess the pharmacodynamic reasons for the failure of HDAC inhibitors in CRPC.
• To contextualize these failures within advancements in understanding CRPC, HDACs, and resistance mechanisms.
• To explore the evolution of androgen receptor-negative prostate cancers, resistance mechanisms, and differential HDAC effects.

Main Methods:

• Review of existing literature on HDAC inhibitors in prostate cancer.
• Analysis of pharmacodynamic data from phase II clinical trials.
• Synthesis of current knowledge on CRPC biology and HDAC functions.

Main Results:

• HDAC inhibitors have demonstrated significant toxicity and limited efficacy in CRPC patients.
• The failure is linked to complex resistance mechanisms and differential effects of HDACs in solid tumors.
• Understanding the specific roles of different HDACs in CRPC is crucial.

Conclusions:

• Extensive characterization of HDACs in prostate tumors is necessary.
• Development of targeted therapies specific to HDAC subtypes could overcome current limitations.
• Future strategies should focus on personalized medicine approaches for CRPC treatment.